Skip to content
Search

Latest Stories

Two pharmacists sentenced to two years for illegally supplying Class C Drugs

Two pharmacists sentenced to two years for illegally supplying Class C Drugs

They unlawfully supplied over 55 million doses of Class C drugs diazepam, zolpidem, and zopiclone

Southwark Crown Court on Thursday sentenced two pharmacists to two years imprisonment each, suspended for 24 months, after they were found guilty of selling ‘industrial’ quantities of Class C controlled drugs.


Mandip Sidhu (47) of Littleover, Derby and Nabeil Nasr (42) of Cheadle, Greater Manchester, pleaded guilty at an earlier hearing following an investigation by the Criminal Enforcement Unit of the Medicines and Healthcare Products Regulatory Authority (MHRA).

Both Sidhu and Nasr were pharmacists registered with the General Pharmaceutical Council at the time of the offenses, which took place between May 2013 and June 2017. Sidhu was the director of Pharmaceutical Health Limited (PHL) in Derby, while Nasr owned several pharmacies across the North West of England.

Sidhu was sentenced to two years imprisonment on each of five counts of supplying Class C drugs and four months for forgery, all to run concurrently and suspended for 24 months. Additionally, she must complete 200 hours of community service for her role in the illegal supply of diazepam, zolpidem, and zopiclone.

Nasr was given a two-year prison sentence for each of two counts of supplying Class C drugs, diazepam and zopiclone, and one year for each of two counts of wholesale dealing without a wholesale licence. He has also been suspended for 24 months on the condition that he completes 200 hours of community service.

They unlawfully supplied over 55 million doses of Class C controlled drugs, with more than 47 million of those doses being diazepam.

Andy Morling, MHRA Deputy Director (Criminal Enforcement), stated that the sentencing followed a thorough and complex investigation conducted by their Criminal Enforcement Unit.

Sidhu also pleaded guilty to a forgery charge, admitting she made a false invoice to mislead an MHRA inspector into believing the medicines had been sold to a company outside the European Economic Area.

The court heard that PHL, the company where Sidhu was a director, purchased 4.27 million tablets in August 2014 and 4.5 million tablets in March 2015, despite not having legally dispensed any medicines against a prescription since July 19, 2013.

To legally trade in these medicines, pharmacists or wholesale business owners are required to possess a Home Office Controlled Drug Licence (HOCDL). Additionally, the licence must be endorsed by the MHRA before it can be used to buy or sell drugs in high quantities. Despite holding various licences for their work as pharmacists, neither Sidhu nor Nasr held an HOCDL, according to MHRA.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less